Enabling Dual‑Payload ADCs Through Site‑Specific Enzymatic Conjugation for Enhanced Stability, Potency, & Manufacturability
- Mitigating systemic toxicity through highly stable, site‑specific enzymatic conjugation that maintains linker integrity and minimizes premature payload release
- Enhancing anti‑tumor activity with hydrophilic, next‑generation linker architectures designed to improve solubility, reduce aggregation, and support dual‑payload loading
- Streamlining bioconjugation workflows with modular, enzyme‑driven manufacturing that enables reproducible DAR control, orthogonality, and scalability for complex ADC formats